Learn More
Model transformations form a key part of MDA (model-driven architecture). Most of the studies deal with the transformations from PIM (platform-independent model) to PSM (platform-specific model) and PSM to Code, but very few deal with the transformation from CIM (computation-independent model) to PIM. This last transformation usually depends on business(More)
BACKGROUND The continuing, randomised, multinational, phase IIB POWER 1 and 2 studies aim to evaluate efficacy and safety of darunavir in combination with low-dose ritonavir in treatment-experienced HIV-1-infected patients. We did a pooled subgroup analysis to update results at week 48 for patients receiving the recommended dose of darunavir-ritonavir(More)
BACKGROUND Non-alcoholic steatohepatitis (NASH) is often accompanied by liver fibrosis, which can progress to cirrhosis; C-C chemokine receptors type 2 and 5 (CCR2/CCR5), which mediate interactions driving inflammation and fibrosis, are promising treatment targets. Cenicriviroc (CVC), a dual-CCR2/CCR5 antagonist, has potent anti-inflammatory and(More)
OBJECTIVE To evaluate the pharmacokinetics of TMC125 (etravirine) and darunavir (DRV) with low-dose ritonavir (DRV/r). DESIGN Open-label, randomized, two-way crossover Phase I trial. METHODS Thirty-two HIV-negative volunteers were randomized 1:1 to two panels. All received TMC125 100 mg twice daily for 8 days and, after 14 days washout, DRV/r 600/100 mg(More)
Acetaminophen (APAP, paracetamol) poisoning is a leading cause of acute liver failure (ALF) in humans and induces hepatocyte necrosis, followed by activation of the innate immune system, further aggravating liver injury. The role of infiltrating monocytes during the early phase of ALF is still ambiguous. Upon experimental APAP overdose in mice,(More)
BACKGROUND AND OBJECTIVE To investigate the potential for pharmacokinetic interactions between the protease inhibitors darunavir (DRV, TMC114) coadministered with low-dose ritonavir (darunavir/r), and atazanavir in HIV-negative, healthy volunteers. METHODS This was an open-label, randomised, three-period, crossover study. Darunavir/r (400/100mg twice(More)
Maritime surveillance of coastal regions requires the processing of a large amount of data. Therefore, limited availability of human or material resources may prevent full use of information and knowledge. A software prototype that incorporates automated association of sensor information with non-sensor information has been developed. Sensor information,(More)
—Two electromagnetic models were used to simulate snow emission at L-band from in situ measurements of snow properties collected at Dome C in Antarctica. Two different approaches were used: one based on the radiative transfer theory, and the other on the wave approach. The Soil Moisture Ocean Salinity (SMOS) satellite observations performed at 1.4 GHz (21(More)
BACKGROUND The present primary analysis of AntiRetroviral Therapy with TMC114 ExaMined In naive Subjects (ARTEMIS) compares the efficacy and safety of once-daily darunavir/ritonavir (DRV/r) with that of lopinavir/ritonavir (LPV/r) in treatment-naive patients. METHODS Patients with HIV-1 RNA at least 5000 copies/ml were stratified by HIV-1 RNA and CD4 cell(More)
BACKGROUND The protease inhibitor darunavir has been shown to be efficacious in highly treatment-experienced patients with HIV infection, but needs to be assessed in patients with a broader range of treatment experience. We did a randomised, controlled, phase III trial (TITAN) to compare 48-week efficacy and safety of darunavir-ritonavir with that of(More)